Publication - Consultation paper

Prostate cancer clinical quality performance indicators: engagement document

Published: 6 May 2016
ISBN:
9781786522542

Document explaining the process of, and inviting engagement on, revision of the prostate cancer QPIs.

Prostate cancer clinical quality performance indicators: engagement document
6. Prostate Cancer Risk Categorisation

6. Prostate Cancer Risk Categorisation

Several factors are known to predict the risk of recurrence of prostate cancer; these factors are used to classify localised prostate cancer into risk categories [4] . Some of the Prostate Cancer QPIs ( section 7) refer to specific risk categories which are detailed in the table below.

Table 1: Localised Prostate Cancer Risk Categories
(adapted from NICE Prostate Cancer: Diagnosis and Treatment Guideline) [4]

Low Risk

Clinical Stage T1 - T2a [a]
and Gleason score ≤ 6
and PSA [b] at diagnosis <10 ug/l

Intermediate Risk

Clinical Stage T2b or T2c
or Gleason score 7
or PSA at diagnosis 10-20 ug/l

High Risk

Clinical Stage T3 - T4
or Gleason score 8-10
or PSA at diagnosis >20 ug/l


Contact